HUNTERDON <HUNT> SETS DENTAL VENTURE
Hunterdon Pharmaceuticals Inc
said it formed a joint venture with <Chesapeake Biological
Laboratories> and <E.B. Michaels Research Associates> to
develop C31G, a substance that may be useful in the treatment
or prevention of plaque.
    The substance, tested in pre-clinical trials at the
University of Pennsylvania, also has other uses as an
anti-fungal or anti-bacterial agent, the company said.
    It said Chesapeake Biological, a private company, owns 55
pct of the venture, E.B. Michaels 10 pct, while it holds the
remaining interest, and the patent for C31G.
 Reuter
